Sign In
Buy BEAM
$32.68
-3.14 (-8.77%)
At Close: Jul 10, 2026
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
10:22am, Thursday, 09'th Jul 2026
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers p
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
01:29pm, Wednesday, 08'th Jul 2026
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
05:45am, Wednesday, 08'th Jul 2026
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
10:35am, Monday, 29'th Jun 2026
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if s
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
11:36am, Friday, 19'th Jun 2026
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU BEAM-304 Program Designed as Platform-based Approach Reflecting Emergin
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
09:51am, Tuesday, 16'th Jun 2026
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
01:10pm, Tuesday, 02'nd Jun 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
01:37pm, Monday, 25'th May 2026
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
02:05pm, Wednesday, 20'th May 2026
Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics licen
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Po
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
02:05pm, Monday, 18'th May 2026
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
12:00pm, Wednesday, 13'th May 2026
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 13, 2026
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
11:49am, Wednesday, 13'th May 2026
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
